MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss - Scorecard - MDSpire

MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss

  • By

  • Jiayao Zhang

  • Yun Zhai

  • Liang He

  • Yunping Song

  • Mingxuan Lu

  • Xuerui Xiang

  • Jiehong Huang

  • Jinyin Huang

  • Weiqing Tian

  • Yue Zhao

  • Shuxian Lin

  • Weicai Liu

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: Regulation of Pathological Bone Loss through Osteoclast Activation Mediated by MiR-1a-3p and Fcgr4 Interaction

At a Glance

CategoryDetail
Condition
Key MechanismsDisrupted homeostasis between osteoclast-mediated bone resorption and osteoblast-mediated bone formation.
Target Population
Care Setting

Key Highlights

  • miR-1a-3p directly targets Fcgr4, inhibiting osteoclast activity.
  • Reduced miR-1a-3p expression correlates with increased osteoclast activity in osteoporosis.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients diagnosed with osteoporosis, particularly those with chronic systemic conditions.

          Current therapies may need to address systemic factors influencing osteoclast activity.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss

            • by Jiayao Zhang, Yun Zhai, Liang He, Yunping Song, Mingxuan Lu, Xuerui Xiang, Jiehong Huang, Jinyin Huang, Weiqing Tian, Yue Zhao, Shuxian Lin, Weicai Liu

            • May 25, 2026

            Related Content

            The Loan Cap That Could Shrink the Doctor Pipeline

            New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

            Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis

            Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation